Breaking Down the FDA Approval of Zanidatamab-Based Regimens in HER2+ Gastric Cancer

In today’s episode, we spoke with Nataliya Uboha, MD, PhD. Dr Uboha is an associate professor and researcher in the Department of Medicine at the University of Wisconsin School of Medicine in Madison.

In our exclusive interview, Dr Uboha discussed the August 2026 FDA approval of zanidatamab (Ziihera)-based regimens for first-line HER2-positive locally advanced or metastatic gastric cancer, and unpacked data from the phase 3 HERIZON-GEA-01 trial (NCT05152147) that supported the regulatory decision. She also shed light on where zanidatamab fits in the gastric cancer treatment paradigm in combination with PD-1 inhibitors like tislelizumab (Tevimbra) and alongside other options like trastuzumab (Herceptin).